151 related articles for article (PubMed ID: 8597748)
1. Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Selegeline is effective and safe in early stages.
MacMahon DG; Bland R
BMJ; 1996 Mar; 312(7032):703; author reply 704-5. PubMed ID: 8597748
[No Abstract] [Full Text] [Related]
2. Effect of adding selegeline to levodopa in early, mild Parkinson's disease. "On treatment" rather than intention to treat analysis should have been used.
Gerlach M; Riederer P; Vogt H
BMJ; 1996 Mar; 312(7032):704; author reply 704-5. PubMed ID: 8597750
[No Abstract] [Full Text] [Related]
3. Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Other studies have not shown increased mortality.
Mäki-Ikola O; Kilkku O; Heinonen E
BMJ; 1996 Mar; 312(7032):702; author reply 704-5. PubMed ID: 8597744
[No Abstract] [Full Text] [Related]
4. Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Patients taking selegeline may have received more levodopa than necessary.
Olanow CW; Godbold JH; Koller W
BMJ; 1996 Mar; 312(7032):702-3; author reply 704-5. PubMed ID: 8597746
[No Abstract] [Full Text] [Related]
5. Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Selegeline may be toxic in presence of increased dopamine concentrations.
Yu PH; Lai CT; Boulton AA
BMJ; 1996 Mar; 312(7032):703-4; author reply 704-5. PubMed ID: 8597749
[No Abstract] [Full Text] [Related]
6. Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Stopping selegeline may lead to problems for patients.
Anderson KE; Girdwood AC; Wilson JA
BMJ; 1996 Mar; 312(7032):702; author reply 704-5. PubMed ID: 8597745
[No Abstract] [Full Text] [Related]
7. Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Causes of death need confirmation.
Jellinger KA
BMJ; 1996 Mar; 312(7032):704-5. PubMed ID: 8597751
[No Abstract] [Full Text] [Related]
8. Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Parkinson's disease is rarely a primary cause of death.
Silva MT; Watts PM; Jenner P
BMJ; 1996 Mar; 312(7032):703; author reply 704-5. PubMed ID: 8597747
[No Abstract] [Full Text] [Related]
9. [Levodopa+selegiline combination and increase of risk of mortality in the treatment of Parkinson disease].
Dubois B; Montastruc JL
Rev Neurol (Paris); 1996 Feb; 152(2):103-5. PubMed ID: 8761616
[No Abstract] [Full Text] [Related]
10. Selegiline: a second look. Six years later: too risky in Parkinson's disease.
Prescrire Int; 2002 Aug; 11(60):108-11. PubMed ID: 12199263
[TBL] [Abstract][Full Text] [Related]
11. Deprenyl in Parkinson's disease.
Korczyn AD; Nisipeanu P
Ann Neurol; 1996 Aug; 40(2):268-9. PubMed ID: 8773617
[No Abstract] [Full Text] [Related]
12. [Drug therapy of Parkinson disease].
Dietrichs E
Tidsskr Nor Laegeforen; 1992 Oct; 112(24):3106-9. PubMed ID: 1471089
[TBL] [Abstract][Full Text] [Related]
13. The effects of early selegiline therapy on long-term levodopa treatment and parkinsonian disability: an interim analysis of a Norwegian--Danish 5-year study. Norwegian-Danish Study Group.
Larsen JP; Boas J
Mov Disord; 1997 Mar; 12(2):175-82. PubMed ID: 9087975
[TBL] [Abstract][Full Text] [Related]
14. Investigation by Parkinson's Disease Research Group of United Kingdom into excess mortality seen with combined levodopa and selegiline treatment in patients with early, mild Parkinson's disease: further results of randomised trial and confidential inquiry.
Ben-Shlomo Y; Churchyard A; Head J; Hurwitz B; Overstall P; Ockelford J; Lees AJ
BMJ; 1998 Apr; 316(7139):1191-6. PubMed ID: 9583926
[TBL] [Abstract][Full Text] [Related]
15. Selegiline and mortality in subjects with Parkinson's disease: a longitudinal community study.
Ben-Shlomo Y; Lees A;
Neurology; 2001 Jul; 57(2):369; author reply 369-70. PubMed ID: 11480425
[No Abstract] [Full Text] [Related]
16. Effect of adding selegiline to levodopa in early, mild Parkinson's disease. Evidence is insufficient to show that combined treatment increases mortality.
Aaltonen H; Kilkku O; Heinonen E; Mäki-Ikola O
BMJ; 1998 Dec; 317(7172):1586-7. PubMed ID: 9890764
[No Abstract] [Full Text] [Related]
17. Deprenyl and levodopa and Parkinson's disease progression.
Fowler JS; Fazzini E; Volkow ND
Ann Neurol; 1996 Aug; 40(2):267-8. PubMed ID: 8773616
[No Abstract] [Full Text] [Related]
18. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial.
Shoulson I; Oakes D; Fahn S; Lang A; Langston JW; LeWitt P; Olanow CW; Penney JB; Tanner C; Kieburtz K; Rudolph A;
Ann Neurol; 2002 May; 51(5):604-12. PubMed ID: 12112107
[TBL] [Abstract][Full Text] [Related]
19. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom.
Lees AJ
BMJ; 1995 Dec; 311(7020):1602-7. PubMed ID: 8555803
[TBL] [Abstract][Full Text] [Related]
20. Protective effect of selegiline in the early and late phases of Parkinson's disease.
Csanda E; Tárczy M
Adv Neurol; 1993; 60():672-5. PubMed ID: 8420208
[No Abstract] [Full Text] [Related]
[Next] [New Search]
